Contributor
Michael J. Rugnetta and Khusboo Desai examine issues regarding racial and ethnic health disparities that need to be addressed in order for personalized medicine to offer the greatest benefit to all.
Michael Rugnetta discusses what personalized medicine is, how it works, and how it can help make people healthier.
Report from Michael Rugnetta and Whitney Kramer offers ways to integrate personalized medicine into our health care system.
Predictably, President Obama has run into some political pushback on last week’s executive order. The complaints have arisen primarily over two issues, neither of which is substantial and both of which deserve to be countered.
The Geron Corporation announced Friday that it will begin Phase I clinical trials on an embryonic stem cell therapy for spinal cord injuries.
Michael Rugnetta and Michael Peroski outline a plan for proceeding with stem cell research and innovation responsibly and ethically.
Report addresses uncertainties that need consideration as genetic medicine gets increasingly personal and the Senate considers genetic non-discrimination legislation.
Opponents try to reverse the 2006 public mandate for stem cell research, but find there are a few kinks in their plan, writes Michael Rugnetta.
NIH’s new plan is overly optimistic about embryonic stem cell alternatives. All stem cells must move forward together to be most effective.
By signing the America COMPETES Act, the president shows he can occasionally be pro-science, writes Michael Rugnetta.
Stem cell opponents’ attempts to block research is making Missouri known as anti-science—a classic case of cutting off the nose to spite the face.
The Washington Post reveals that close Bush and Cheney family friend blocked key global health report from the surgeon general.